{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T19:58:58Z","timestamp":1762459138245},"reference-count":5,"publisher":"Editorial Committee of Annals of Thoracic and Cardiovascular Surgery","issue":"Supplement","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Thorac Cardiovasc Surg","ATCS"],"published-print":{"date-parts":[[2014]]},"DOI":"10.5761\/atcs.cr.13-00141","type":"journal-article","created":{"date-parts":[[2014,2,3]],"date-time":"2014-02-03T23:07:13Z","timestamp":1391468833000},"page":"674-676","source":"Crossref","is-referenced-by-count":8,"title":["Does Gefitinib Have Effects on EGFR Mutation-Positive Thymoma? \u2014Case Report of Thymoma Recurrence"],"prefix":"10.5761","volume":"20","author":[{"given":"Tomoyuki","family":"Nakagiri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soichiro","family":"Funaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihisa","family":"Kadota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukiyasu","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Shiono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akinori","family":"Akashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meinoshin","family":"Okumura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3757","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Kurup A, Burun M, Dropcho S, et al. Phase II study of gefitinib treatment in advanced thymic malignancies. J Clin Oncol 2005; 23: 7068.","DOI":"10.1200\/jco.2005.23.16_suppl.7068"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Yoh K, Nishiwaki Y, Ishii G, et al. Mutational status of EGFR and KIT in thymoma and thymic carcinoma. Lung Cancer 2008; 62: 316-20.","DOI":"10.1016\/j.lungcan.2008.03.013"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Suzuki E, Sasaki H, Kawano O, et al. Expression and mutation statuses of epidermal growth factor receptor in thymic epithelial tumors. Jpn J Clin Oncol 2006; 36: 351-6.","DOI":"10.1093\/jjco\/hyl028"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Palmieri G, Marino M, Salvatore M, et al. Cetuximab is an active treatment of metastatic and chemorefractory thymoma. Front Biosci 2007; 12: 757-61.","DOI":"10.2741\/2098"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Kelly RJ, Petrini I, Rajan A, et al. Thymic malignancies: from clinical management to targeted therapies. J Clin Oncol 2011; 29: 4820-7.","DOI":"10.1200\/JCO.2011.36.0487"}],"container-title":["Annals of Thoracic and Cardiovascular Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/atcs\/20\/Supplement\/20_cr.13-00141\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T23:54:55Z","timestamp":1621554895000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/atcs\/20\/Supplement\/20_cr.13-00141\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":5,"journal-issue":{"issue":"Supplement","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.5761\/atcs.cr.13-00141","relation":{},"ISSN":["1341-1098","2186-1005"],"issn-type":[{"value":"1341-1098","type":"print"},{"value":"2186-1005","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014]]}}}